Drug Profile


Alternative Names: 256U; 256U87; BW 256; BW 256U; Talavir; Valacyclovir; Valherpes; Valtrex; Vapridol; Virval; Zelitrex

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antivirals; Branched-chain amino acids; Essential amino acids; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cytomegalovirus infections; Herpes simplex virus infections; Herpes zoster; Herpesvirus infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Jun 2015 No recent reports on development identified - Phase-III for Herpes simplex virus infections (Prevention) in Japan (PO)
  • 01 Mar 2015 GlaxoSmithKline completes a phase II trial for Hepatitis C in USA (NCT01580995)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top